Vanguard Global Advisers’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
Other funds holding AVIR
BCM
Vanguard Global Advisers's AVIR Position: Q3 2026 in Review
Vanguard Global Advisers increased its Atea Pharmaceuticals (AVIR) stake by 1.4% in Q3 2026, buying an estimated $1.84K and bringing the position to 26,040 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #2637.
Vanguard Global Advisers first reported a position in AVIR in Q1 2026 and has held it in 3 quarters since. The position peaked at $138K in Q1 2026. 127 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.
- Vanguard Global Advisers held 26,040 shares of Atea Pharmaceuticals worth $136K as of Q3 2026.
- Vanguard Global Advisers bought 359 Atea Pharmaceuticals shares in Q3 2026, an estimated $1.84K.
- Atea Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2637 holding.
- Vanguard Global Advisers first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Atea Pharmaceuticals position peaked at $138K in Q1 2026.
- 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.